Terran Biosciences, Inc. v. Compass Pathfinder Limited

District Court, D. Maryland·Decided May 2, 2024·No. 1:22-cv-01956·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MARYLAND

TERRAN BIOSCIENCES, INC., et al. Plaintiffs, v. Civil Action No. ELH-22-1956 COMPASS PATHFINDER LIMITED, et al., Defendants.

MEMORANDUM OPINION Terran Biosciences, Inc. (“Terran Biosciences”), a Delaware corporation; Scott Thompson, Ph.D., formerly Professor of Physiology and Chair of the Department of Physiology at the University of Maryland School of Medicine; and the University of Maryland, Baltimore (“University” or “UMB”) (collectively, “Terran”), are plaintiffs in a suit against defendant Compass Pathfinder Limited, a company incorporated in England and Wales, and ten “John Doe” defendants (collectively, “Compass”). ECF 81 (“Third Amended Complaint”), ¶¶ 1, 9–13.1 Plaintiffs claim that Compass defrauded them of trade secrets concerning the therapeutic application of the hallucinogenic compound psilocybin. Id. ¶ 1. In several of the parties’ respective submissions, the parties have referred to or quoted a “Master Licensing Agreement” (“MLA”) between Terran Biosciences and the University. See,

1 Thompson and the University were not plaintiffs to the original suit. See ECF 1. Thompson was added as a plaintiff in the Second Amended Complaint. ECF 47; ECF 48. Later, Terran Biosciences and Thompson sought leave to file a Third Amended Complaint. ECF 67. Among other things, they sought to join the University, a state entity, as a co-plaintiff. See id. I granted that request by Memorandum Opinion and Order of February 6, 2024. ECF 79; ECF 80. e.g., ECF 51-1; ECF 68; ECF 81; ECF 93-1. In addition, Compass has filed the MLA, under temporary seal, as an exhibit to two of its submissions. ECF 51-3; ECF 68-2. According to Terran, the MLA contains commercially sensitive information and the competitive standing of Terran Biosciences would be damaged if it were made public. ECF 83. Therefore, Terran has moved to seal the MLA in its entirety or, alternatively, in part. ECF 83 (the

“Motion” or “Motion to Seal”). The Motion is supported by several exhibits. See ECF 83-1 to ECF 83-3. Terran has also asked the Court to “keep under seal the redacted portions of the motion papers that quote the MLA.” ECF 83 at 1. Terran appears to identify the “motion papers” it seeks to seal as the submissions docketed at ECF 51-1, ECF 51-3, ECF 68, ECF 68-2, and ECF 75.2 In support of the Motion, Terran has submitted a “Declaration of Dustin Tetzl” (ECF 83- 3, “Tetzl Declaration”), the Chief Business Officer at Terran Biosciences. Id. ¶ 1. Terran has also submitted a copy of the MLA that identifies, by yellow highlighting, “the most sensitive information” in the MLA, which Terran proposes to redact if the Court declines to seal the MLA in its entirety. ECF 83 at 2 n.2; see ECF 83-1; ECF 84. And, Terran has submitted a copy of the

MLA that includes the proposed redactions. ECF 83-2; ECF 85. According to Terran, this version of the MLA “could be filed on the public docket if the Court denies [Terran’s] request to seal the MLA in full.” ECF 83 at 2 n.2. Terran has moved to temporarily seal the redacted and highlighted versions of the MLA (ECF 84; ECF 85), pending the Court’s decision on the Motion to Seal. See ECF 86 (“Terran’s Motion for Temporary Seal”). Notably, Compass does not oppose the Motion to Seal. ECF 87. Terran has submitted a Reply. ECF 92.

2 Since Terran filed the Motion to Seal, the parties have filed several additional submissions under seal. ECF 84; ECF 85; ECF 93; ECF 102; ECF 105. After Terran filed the Motion to Seal, Compass filed a motion to dismiss the Third Amended Complaint. ECF 93; ECF 93-1 to ECF 93-6 (collectively, “Third Motion to Dismiss”). Compass has asked the Court to temporarily seal portions of the Third Motion to Dismiss. ECF 94 (“Compass’s Motion for Temporary Seal”). No hearing is necessary to decide the motions. See Local Rule 105.6. For the reasons that

follow, I shall grant the Motion to Seal (ECF 83), in part; deny, as moot, Terran’s Motion for Temporary Seal (ECF 86); and grant Compass’s Motion for Temporary Seal (ECF 94). I. Background Terran has amended its lawsuit three times. See ECF 1 (original Complaint); ECF 34 (First Amended Complaint); ECF 48 (Second Amended Complaint); ECF 81 (Third Amended Complaint). In each version of the suit, Terran has referred to and described certain provisions of the MLA that, in its view, establish the right of Terran to sue for misappropriation of the psilocybin trade secrets. See ECF 1, ¶¶ 29–30; ECF 34, ¶¶ 35–36; ECF 48, ¶¶ 50–51; ECF 81, ¶¶ 52–53. Of relevance here, Compass moved to dismiss the Second Amended Complaint. ECF 51;

ECF 51-1 to ECF 51-8 (collectively, “Second Motion to Dismiss”). In the Second Motion to Dismiss, Compass cited certain provisions of the MLA in support of its arguments that the University, as “a co-owner” of the alleged trade secrets, was a necessary party under Fed. R. Civ. P. 19, ECF 51-1 at 31,3 and that the putative trade secrets were not subject to reasonable measures of secrecy. Id. at 34–35; see also id. at 10–11 (referring to the MLA in discussion of procedural history). Compass also filed the MLA as an exhibit to the Second Motion to Dismiss. ECF 51-3. At Terran’s request, Compass filed a “Motion to Seal Unredacted Memorandum of Law in Support of Compass[’s] . . . Motion to Dismiss and Exhibit A Thereto.” ECF 52 (“First Motion to

3 At the time, the University had not joined the lawsuit as a plaintiff. Seal”). In the First Motion to Seal, Compass stated that it “intend[ed] to file a public version of its [Second] Motion to Dismiss from which the confidential information concerning the [MLA] has been redacted.” Id. at 1–2. In addition, Compass “request[ed] that it be allowed to file,” under seal, “the unredacted version of its Motion to Dismiss [ECF 51-1]” and the exhibit containing the MLA (ECF 51-3). ECF 52 at 2 (emphasis in ECF 52). The Court granted Compass’s First Motion

to Seal. ECF 54. Therefore, the unredacted version of the Second Motion to Dismiss, and the exhibit containing the MLA, were filed under seal. See ECF 51-1; ECF 51-3. And, the redacted version of the Second Motion to Dismiss was filed on the public docket at ECF 53-1. Terran opposed the Second Motion to Dismiss. ECF 55; ECF 55-1 to ECF 55-7 (“Opposition to the Second Motion to Dismiss” or “Opposition”). In the Opposition, Terran quoted § 7.1.2 of the MLA, which provides, in part: “The Inventions . . . will be deemed both parties’ Confidential Information regardless of the disclosing party and each party will owe confidentiality and non-use obligation [sic] to the other party hereunder.” ECF 55-1 at 27 (quoting ECF 51-3 at 23). Terran also stated that the MLA “includes a development plan setting forth in

extensive detail Terran [Biosciences’s] intention to commercialize the Psilocybin Trade Secrets.” ECF 55-1 at 29 n.7 (citing ECF 51-3 at 46–58). However, Terran did not provide any details of the plan to commercialize the psilocybin trade secrets. See ECF 55-1. Moreover, Terran did not redact the references to and descriptions of the MLA from its public filings. Before the Court ruled on the Second Motion to Dismiss, Terran filed a “Motion for Leave to File Third Amended Complaint,” seeking, inter alia, the joinder of UMB as a plaintiff. ECF 67 (“Motion for Leave”). Compass opposed the Motion for Leave. ECF 68 (“Leave Opposition”). In the Leave Opposition, Compass referred to and quoted the MLA in support of its contention that Terran Biosciences’s request to join the University as a plaintiff was untimely. Id. at 16.

Free access — add to your briefcase to read the full text and ask questions with AI

Terran Biosciences, Inc. v. Compass Pathfinder Limited, (D. Md. 2024).

Terran Biosciences, Inc. v. Compass Pathfinder Limited (Terran Biosciences, Inc. v. Compass Pathfinder Limited) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Nixon v. Warner Communications, Inc.
435 U.S. 589 (Supreme Court, 1978)
KRUPSKI v. COSTA CROCIERE S. P. A
560 U.S. 538 (Supreme Court, 2010)
Company Doe v. Public Citizen
749 F.3d 246 (Fourth Circuit, 2014)
Gordon Goines v. Valley Community Services Board
822 F.3d 159 (Fourth Circuit, 2016)
Sky Angel U.S., LLC v. Discovery Communications, LLC
885 F.3d 271 (Fourth Circuit, 2018)
United States v. Christopher Harris
890 F.3d 480 (Fourth Circuit, 2018)
United States v. John Doe
962 F.3d 139 (Fourth Circuit, 2020)
Ansberto Gonzalez v. Kenneth Cuccinelli, II
985 F.3d 357 (Fourth Circuit, 2021)
Sky Angel U.S., LLC v. Discovery Communications, LLC
95 F. Supp. 3d 860 (D. Maryland, 2015)
United States v. Appelbaum
707 F.3d 283 (Fourth Circuit, 2013)
Dorsey v. TGT Consulting, LLC
888 F. Supp. 2d 670 (D. Maryland, 2012)
Minter v. Wells Fargo Bank, N.A.
258 F.R.D. 118 (D. Maryland, 2009)
United States v. Soussoudis
807 F.2d 383 (Fourth Circuit, 1986)